Mizuho Reiterates Relmada (RLMD) at Buy, REL-1017 Setting Up for Meaningful Commercial Opportunity, Peak Sales Estimated at $1.03B
Tweet Send to a Friend
Mizuho Securities analyst Vamil Divan reiterated a Buy rating and $50.00 price target on Relmada Therapeutics Inc (NASDAQ: RLMD) on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
